Mitogen activated protein kinase inhibitors: Where are we now and where are we going?

Annals of the Rheumatic Diseases

Volumn 65, Issue SUPPL. 3, 2006, Pages

  Sweeney, S E ^a   Firestein, G S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; AS 600292; AS 601245; BENZAZOLE DERIVATIVE; CC 401; CELGENE; CEP 1347; CEPHALON; COLLAGEN; CYTOKINE; DORAMAPIMOD; IBUPROFEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PD 0325901; PROTEIN P53; PROTEIN P53 INHIBITOR; SCIO 469; SULFONAMIDE; SULPHONYL AMINO ACID; SULPHONYL HYDRAZIDE; UNCLASSIFIED DRUG; VX 702;

CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DOSE RESPONSE; DRUG ERUPTION; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE MEDIATED INJURY; INFECTION; INFLAMMATORY DISEASE; LIVER DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RHEUMATIC DISEASE; TARGET CELL; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS;

EID: 33750341495     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.058388     Document Type: Conference Paper

References (39)

1. Manning A, Davis R. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003;2:554-65.
2. Schett G, Tonidast-Akrad M, Smolen JS, et al. Activation, differentiation localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
3. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291:124-30.
4. Kuchen S, Seemayer C, Rethage J, von Knoch R, Kuenzler P, Beat AM, et al. The L1 retroelement-related p40 protein induces p38delta MAP kinase. Autoimmunity 2004;37:57-65.
5. Sundarrajan M, Boyle DL, Chabaud-Riou M, Hammaker D, Firestein GS. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 2003;48:2450-60.
6. Badges A, Griswold D, Kapadia R, Blake S, Swift BA, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:175-83.
7. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81.
8. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54:463-72.
9. Inoue T. MKK3 is the pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci U S A 2006;103:5484-9.
10. Dong C, Yang D, Wysk M, Whitmarsh A, Davis R, Flavell R. Defective T cell differentiation in the absence of Jnk1. Science 1998;282:2092-5.
11. Bennett B, Sasaki D, Murray B, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrozolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-6.
12. Bain J, McLauchlan H, Elliot M, Cohen P. The specificity of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
13. Han Z, Boyle D, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
14. Han Z, Chang L, Yamanishi Y, Karin M, Firestein G. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002;46:818-23.
15. Koller M, Hayer S, Redlich K, et al. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Ther 2005;7:R166-73.
16. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 2005;48:4596-607.
17. Yasuda J, Whitmarsh A, Cavanagh J, Sharma M, Davis R. The JIP group of mitogen-activated protein kinase scaffold proteins. Mol Cell Biol 1999;19:7245-54.
18. Jaeschke A, Czech M, Davis R. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Gene Dev 2004;18:1976-80.
19. Barr R, Kendrick T, Bogoyevitch M. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002;277:10987-97.
20. Borsello T, Clarke P, Hirt L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicily and cerebral ischemia. Nat Med 2003;9:1180-6.
21. Barr R, Boehm I, Attwood P, Watt P, Bogoyevitch M. The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J Biol Chem 2004;279:36327-38.
22. Xia X, Hording T, Weller M, Bieneman A, Uney J, Schulz J. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:10433-8.
23. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002;30:94-9.
24. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005;152:37-42.
25. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75.
26. Hollenbach E, Vieth M, Roessner A, Neumann M, Malfertheiner P, Naumann M. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005;280:14981-8.
27. Escott K, Belvisi M, Birrell M, Webber S, Foster M, Sargent C. Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br J Pharmacol 2000;131:173-0.
28. Grammer A, Fischer R, Lee O, Zhang X, Lipsky P. Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 2004;6:28-38.
29. Eynott P, Xu L, Bennett B, et al. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology 2004;112:446-53.
30. Nath P, Eynott P, Leung S, Adcock I, Bennelt B, Chung K. Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur J Pharmacol 2005;506:273-83.
31. Fijen J, Zijlstra J, De Boer P, Spanjersberg R, Tervaert JW, Van Der Werf TS, et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001;124:16-20.
32. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002;168:4070-7.
33. Ji R. Mitogen-activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs 2004;5:71.
34. Scapin G, Patel S, Lisnock J, Becker J, LoGrasso P. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol 2003;10:705-12.
35. Ruckle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, et al. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene suifonamide inhibitors of c-Jun-N-terminal kinase. J Med Chem 2004;47:6921-34.
36. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14.
37. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34.
38. Hittti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006;26:2399-407.
39. Inoue T, Hammaker D, Boyle D, Firestein GS. Regulation of JNK by MKK7 in fibroblast-like synoviocytes. Arthritis Rheum 2006;54:2127-35.